[v] Wang, Y., & Roberts, C
As consumer demand for prescription GLP-1 weight-management medications continues to expand, telehealth platforms offering physician-supervised treatment options have emerged as a rapidly growing segment of the healthcare market
Retatrutide, a triple agonist targeting gastric inhibitory polypeptide (GIP), GLP-1, and glucagon receptors, has achieved highly promising outcomes in its phase 2 trial [22], with weight loss up to 24%
Previous research declaimed that exposure to maternal hormone may develop ASD
doi: 10.1016/j.jri.2020.103252 90 ShokriM-RBozorgmehrMGhanavatinejadAFalakRAleahmadMKazemnejadSet al
Others fear they will try and fail again